Nuclear Medicine

Spago Nanomedical moves to delist from Nasdaq First North

By AuntMinnieEurope.com staff writers

The move is intended to improve the company’s ability to finance further development of its Tumorad (lutetium-177 SN201) program.

October 26, 2026

AdvanCell reports data on Pb-212 PSMA therapy

By AuntMinnie.com staff writers

Eighty percent of patients had a prostate-specific antigen (PSA) decline of at least 50%, according to the company.

October 26, 2026

EANM: Is ‘research fragmentation’ holding back nuclear medicine?

By Will Morton

Well-designed studies require collaboration among nuclear medicine, medical oncology, urology, radiation oncology, and clinical trial support.

October 21, 2026

EANM: AI studies target tumor boards, PET/CT protocoling, and PD-L1 prediction

By Claudia Tschabuschnig

A multi-agent AI system improved tumor board recommendations, while other studies explored PET/CT protocol selection and cancer biomarker prediction at EANM 2026 in Vienna.

October 20, 2026

EANM: Lu-177 edotreotide dose linked to tumor response

By AuntMinnieEurope.com staff writers

Objective response rates climbed from 12% in the lowest dose quartile to 64% in the highest.

October 20, 2026

EANM 2026 opened with Nobel lessons and waltz

By Claudia Tschabuschnig

The opening ceremony of EANM 2026 combined scientific inspiration with a Viennese waltz.

October 19, 2026

Video from EANM: President Erba on radiopharmaceuticals, PET, and AI

By Claudia Tschabuschnig

Advances in radiopharmaceuticals, PET imaging, and AI are driving personalized nuclear medicine, according to EANM President Prof. Paola Anna Erba.

October 19, 2026

EANM 2026: How early is early enough in prevention?

By Claudia Tschabuschnig

Experts question whether PET-based screening is ready for cancer, heart disease, and Alzheimer’s, and what evidence would justify it.

October 19, 2026

EANM: Thomas Hope on what’s next in FAP-targeted theranostics

By Will Morton

The innovations and work being done to optimize FAP agents will likely "spill over" to other targets.

October 19, 2026

EANM: Affibody presents data on HER2 radioligand therapy

By AuntMinnieEurope.com staff writers

The Stockholm, Sweden-based company is highlighting progress across its radiopharmaceutical pipeline.

October 19, 2026

EANM: Akiram presents first clinical data for CD44v6-targeted therapy

By AuntMinnieEurope.com staff writers

The first-in-human ongoing phase I trial is evaluating Lu-177 AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumors.

October 19, 2026

Nuclidium, NorthStar sign Cu-67 supply and manufacturing deal

By AuntMinnie.com staff writers

Cu-67 is the therapeutic half of Nuclidium’s theranostic platform, which pairs it with copper-61 (Cu-61) for diagnostic imaging.

October 19, 2026

Page 1 of 7

Next Page